Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
Sell
19
ALVO Quote, Financials, Valuation and Earnings
Last price:
$9.36
Seasonality move
:
-9.62%
Day range:
$7.90 - $8.10
52-week range:
$7.35 - $14.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.34x
P/B ratio:
--
Volume:
183K
Avg. volume:
140.5K
1-year change:
-42.71%
Market cap:
$2.4B
Revenue:
$489.7M
EPS (TTM):
-$0.87
Analysts' Opinion
-
Consensus RatingAlvotech has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.00, Alvotech has an estimated upside of 126.7% from its current price of $7.94.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing -76.32% downside risk from its current price of $7.94.
Fair Value
-
According to the consensus of 4 analysts, Alvotech has 126.7% upside to fair value with a price target of $18.00 per share.
ALVO vs. S&P 500
-
Over the past 5 trading days, Alvotech has overperformed the S&P 500 by 2.27% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Alvotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alvotech has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Alvotech reported revenues of $151.2M.
Earnings Growth
-
Alvotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Alvotech reported earnings per share of -$0.24.
Enterprise value:
3.4B
EV / Invested capital:
--
Price / LTM sales:
4.34x
EV / EBIT:
45.52x
EV / Revenue:
6.97x
PEG ratio (5yr expected):
-0.13x
EV / Free cash flow:
-11.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
33.33x
Gross Profit (TTM):
$304.4M
Return On Assets:
-20.95%
Net Income Margin (TTM):
-47.35%
Return On Equity:
--
Return On Invested Capital:
-54.24%
Operating Margin:
8.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $83M | $91.4M | $489.7M | $53.4M | $151.2M | |
| Gross Profit | $18.9M | -$69.4M | $304.4M | -$3M | $70.9M | |
| Operating Income | -$346.4M | -$354.9M | $69.6M | -$77.2M | $13.5M | |
| EBITDA | -$453.8M | -$493.7M | -$32.3M | -$276.7M | -$120M | |
| Diluted EPS | -$2.33 | -$2.43 | -$0.87 | -$1.22 | -$0.24 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $119.8M | $230.7M | $194.8M | $455M | |
| Total Assets | -- | $598M | $828.4M | $950.1M | $1.2B | |
| Current Liabilities | -- | $111.8M | $167.3M | $261M | $193.4M | |
| Total Liabilities | -- | $733.6M | $1.4B | $1.9B | $1.6B | |
| Total Equity | -- | -$135.6M | -$564.4M | -$932.5M | -$412.8M | |
| Total Debt | -- | $400.9M | $764.6M | $960.2M | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$312.4M | -$312.2M | -$236.8M | -$67.2M | -$39.2M | |
| Cash From Investing | -$63.5M | -$46.3M | -$18.9M | -$10.5M | -$31.1M | |
| Cash From Financing | $424.9M | $301.3M | $297.3M | $20.7M | $4.3M | |
| Free Cash Flow | -$361.4M | -$358.7M | -$293.8M | -$77.6M | -$70.3M | |
ALVO
Sector
Market Cap
$2.4B
$34.5M
Price % of 52-Week High
54.2%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
-4.56%
-0.79%
1-Year Price Total Return
-42.71%
-42.08%
Beta (5-Year)
--
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.03
200-day SMA
Sell
Level
$11.54
Bollinger Bands (100)
Sell
Level
9.34 - 13.02
Chaikin Money Flow
Sell
Level
-15.7M
20-day SMA
Sell
Level
$8.25
Relative Strength Index (RSI14)
Sell
Level
36.38
ADX Line
Sell
Level
42.24
Williams %R
Neutral
Level
-74.3119
50-day SMA
Sell
Level
$9.72
MACD (12, 26)
Sell
Level
-0.48
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
18.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.842)
Sell
CA Score
(Annual)
Level (-5.6924)
Buy
Beneish M-Score
(Annual)
Level (-3.9792)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (6.794)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Stock Forecast FAQ
In the current month, ALVO has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The ALVO average analyst price target in the past 3 months is $18.00.
-
Where Will Alvotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alvotech share price will rise to $18.00 per share over the next 12 months.
-
What Do Analysts Say About Alvotech?
Analysts are divided on their view about Alvotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alvotech is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Alvotech's Price Target?
The price target for Alvotech over the next 1-year time period is forecast to be $18.00 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is ALVO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alvotech is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of ALVO?
You can purchase shares of Alvotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alvotech shares.
-
What Is The Alvotech Share Price Today?
Alvotech was last trading at $9.36 per share. This represents the most recent stock quote for Alvotech. Yesterday, Alvotech closed at $7.94 per share.
-
How To Buy Alvotech Stock Online?
In order to purchase Alvotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Is it Safe to Invest in Google With OpenAI Threats?
For the last 20 years, Google parent company Alphabet (NASDAQ:GOOG,…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
